Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

PrOD ± ribavirin highly effective in HCV patients with advanced hepatic fibrosis, compensated cirrhosis

18 May 2019
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

Use of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin is very effective in the treatment of chronic hepatitis C with advanced hepatic fibrosis or compensated cirrhosis, according to a recent study, adding that Child-Pugh A6 must be an exclusion criterion for first-line treatment in these patients.

Of the 898 patients, 887 (98.8 percent) achieved sustained virologic response 12 weeks off therapy (SVR12) based on the per-protocol analysis (patients receiving ≥1 dose of any study medication and hepatitis C virus (HCV) RNA data available at post-treatment week 12). The only significant factor of poor SVR12 was Child-Pugh A6 (odds ratio [OR], 0.168; 95 percent CI, 0.043–0.659; p=0.011).

Fifty-four (5.7 percent) patients discontinued treatment due to hepatic decompensation (n=18; 1.9 percent) and other adverse reactions. In multivariate analyses, old age (OR, 1.062; 1.008–1.119; p=0.024) and Child-Pugh A6 (OR, 4.957; 1.691–14.528; p=0.004) significantly correlated with hepatic decompensation.

The authors enrolled 941 patients treated in four hospitals (the Keelung, the Linkuo, the Chiayi and the Kaohsiung Chang Gung Memorial Hospital) through a nationwide government-funded programme in Taiwan. Patients with HCV and advanced hepatic fibrosis or compensated cirrhosis received 12 weeks of PrOD for HCV-1b and 12 or 24 weeks of PrOD plus ribavirin therapy for HCV-1a without or with cirrhosis.

Ultrasonography, fibrosis index based on 4 factors (FIB-4) test, or transient elastography/acoustic radiation force impulse (ARFI) was used to confirm the advanced hepatic fibrosis or compensated cirrhosis in patients. Safety and efficacy of PrOD were evaluated.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.